USFDA inspects Strides Pharma’s Bengaluru facility, gets EIR with Zero 483 Observations

BANGALURU | MUMBAI | RAJKOT – US FDA (Food & Drugs Administration) successfully inspected Strides Pharma Sciences Ltd’s formulations facility (KRSG Gardens) in  Bengaluru and the facility has  received the Establishment Inspection Report (EIR), there by confirming the successful  closure of the inspections, the company said in Press Release submitted to the Indian Stock Exchanges on Wednesday.

The inspection conducted in November 2018 had concluded  with Zero 483 observations , the release read.

The flagship facility in Bangalore manufacturers tablets, capsules, liquids, creams  ointments, sachets.

The facility is the largest for company and supports several current  and future products for the US markets.

The Press Release from the company had hit the Indian Bourses prior to opening of trading session, resulting immediate spike in the share price of the company, as soon as trading session kicked-off on Indian Bourses on Wednesday.

Later the stock failed to maintain trader-investor interest, further ending in RED Zone on negative counters, as the trading session, for the day ended.